Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Forward-looking Statements




We and our representatives may from time to time make written or oral statements
that are "forward-looking," including statements contained in this quarterly
report and other filings with the Securities and Exchange Commission (the
"SEC"), reports to our stockholders and news releases. All statements that
express expectations, estimates, forecasts or projections are forward-looking
statements. In addition, other written or oral statements which constitute
forward-looking statements may be made by us or on our behalf. Words such as
"expect," "anticipate," "intend," "plan," "believe," "seek," "estimate,"
"project," "forecast," "may," "should," variations of such words and similar
expressions are intended to identify such forward-looking statements. These
statements are not guarantees of future performance and involve risks,
uncertainties and assumptions which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is expressed or forecasted
in or suggested by such forward-looking statements. We undertake no obligation
to update or revise any of the forward-looking statements after the date of this
quarterly report to conform forward-looking statements to actual results.
Important factors on which such statements are based on assumptions concerning
uncertainties, including but not limited to, uncertainties associated with the
following:


· Inadequate capital and barriers to raising the additional capital or to

      obtaining the financing needed to implement our business plans;
   ·  Our failure to earn revenues or profits;
   ·  Inadequate capital to continue business;
   ·  Volatility or decline of our stock price;
   ·  Potential fluctuation in quarterly results;
   ·  Rapid and significant changes in markets;

· Litigation with or legal claims and allegations by outside parties; and

· Insufficient revenues to cover operating costs.




The following discussion should be read in conjunction with the financial
statements and the notes thereto which are included in this quarterly report.
This discussion contains forward-looking statements that involve risks,
uncertainties and assumptions. Our actual results may differ substantially from
those anticipated in any forward-looking statements included in this discussion
as a result of various factors.



Background



American CryoStem Corporation was incorporated in the state of Nevada on March
13, 2009. On April 20, 2011, we acquired, through our wholly owned subsidiary
American CryoStem Acquisition Corporation, substantially all of the assets from,
and assumed substantially all of the liabilities of, ACS Global, Inc. ("ACS") in
exchange for our issuance of 21,000,000 shares of Common Stock to ACS (the
"Asset Purchase"). We filed a Current Report on Form 8-K with the Securities and
Exchange Commission (SEC) on April 27, 2011 disclosing the Asset Purchase and
certain related matters.

12





Overview



American CryoStem Corporation is a biotechnology pioneer in the field of
Regenerative and Personalized Medicine and operates a state-of-the-art,
FDA-registered, clinical laboratory dedicated to standardized processing,
bio-banking and development of cellular tools and applications using autologous
adipose (fat) tissue and adipose derived stem cells ("ADSCs"). The Company has
built a strong, strategic portfolio of intellectual property, patent
applications, and proprietary operating processes that form its core
standardized cellular platform which we believe supports and promotes a growing
pipeline of biologic products and processes, clinical services and international
licensing opportunities. Our FDA registered clinical laboratory which we believe
to be in compliance with FDA regulations for human tissue processing,
cryo-storage and cell culture and differentiation media development is located
in Monmouth Junction, New Jersey.



The Company believes the reproducibility of scientific studies has become a
substantial issue in life science research from drug discovery and development
through clinical trials as researchers throughout the world continue to use
different protocols for processes associated with sample preparation,
cryopreservation and cold chain management. We believe by standardizing
handling, storage, and transportation protocols we can substantially improve the
quality and reproducibility of preclinical and clinical data to help accelerate
the transition from lab research to product development and market launch.



Our business strategy is centered on marketing our standardized collection and
processing platform and products as a complete adipose stem cell solution. We
are expanding our international laboratory and product footprint, through
internal research and development and scientific collaborations. We intend to
generate revenue through the sale and licensing of our patented collection,
processing and storage products, laboratory tools, and physician/researcher
services to attempt to capitalize on: (1) ADSC technologies; (2) scientific
breakthroughs incorporating ADSCs that have been developing in the fast growing
Regenerative and Personalized Medicine industries; (3) providing these growth
industries with a standardized ADSC cell processing platform; (4) enhancing the
delivery of healthcare through cellular-based therapies and applications which
address disease treatment, wound and burn healing, joint repair and personalized
health and beauty care; and (5) building a global network of physicians and
affiliated laboratory facilities for the delivery of our products and services.



Our proprietary, patent pending clinical processing platform allows for the
collection, preparation and cryo-preservation of adipose tissue without
manipulation, bio-generation or the addition of animal-derived products or other
chemical materials which require removal from the tissue sample upon retrieval
or prior to use. Management believes this core process makes each tissue sample
suitable for use in cosmetic grafting procedures or for further processing to
adult stem cells for other types of stem cell therapies. Currently, we believe
there are numerous therapeutic and orthopedic applications for adipose tissue
and adult stem cell treatments identified or in use globally. As of May 1, 2017,
a review of clinicaltrials.gov, operated by the US National Institutes of Health
(NIH) indicates that there is a significant number of clinical trials registered
or completed that are focused on adipose tissue (2243), adult stem cells (5277),
adipose derived stem cells (204), mesenchymal stem cells (744), and stromal
vascular fraction (81).



Products and Services



American CryoStem is focused on multiple high margin business lines capable of
generating sustainable, recurring revenue streams from each of our developed
products and services. The Company also incorporates its proprietary and
patented or patent pending laboratory products, such as our ACSelerate™ cell
culture, transportation and cryopreservation mediums, into our processing
product production and contract manufacturing services. Additionally, the
Company requires licensees of our tissue and cell processing technologies to
purchase our consumable products including our CELLECT© collection kit,
ACSelerate Max cell culture media, and ACSelerate-CP adipose tissue
cryoprotectant for the collection, processing, expansion and storage of
tissue/stem cells.



We have generated initial revenues from our licensee's in Japan and Hong Kong
and subject to, obtaining the requisite financing; management believes that we
are well positioned to leverage our developed products and services as the basis
for expansion of international distribution through licensees of our
technologies for a host of Regenerative Medicine uses and future applications.

13




Our branded product and service offerings include:




CELLECT® Validated Collection, Transportation, and Storage System - An
unbreakable "chain of custody" clinical solution for physicians or researchers
to collect and deliver tissue samples utilizing proprietary and patent pending
methods and materials. The CELLECT® service is monitored in real-time and
assures the highest cell viability upon laboratory receipt. The CELLECT® system
incorporates our ACSelerate-TR™ transport medium into all collection bags which
supports the health of the tissue during transport. The CELLECT® kit is an
integral part of our validated ATGRAFT™ and ATCELL™ technology platform to be
used by all licensees of our platform technologies.



American CryoStem is the first tissue bank to globally incorporate through its
CELLECT® service the International Blood Banking identification and labeling and
product identification coding system. The coding was developed in conjunction
with the American Association of Blood Banks (AABB), the American Red Cross and
the International Society of Blood Transfusion (ISBT). These groups form the
International Council for Commonality in Blood Banking Automation (ICCBBA) and
developed the ISBT 128 Standard for machine readable labeling. This labeling
system is an acceptable machine readable labeling standard, product description,
and bar coding system for FDA Center for Biologics Evaluation and Research under
21 CFR 606.12(c) 13. American CryoStem conforms to this standard in its
laboratory facility and all cellular and tissue products produced at the
facility carry our W3750 ICCBBA facility identifier allowing any hospital,
clinic, laboratory and regulator worldwide to identify the origin and obtain
additional information on any sample produced at an American CryoStem facility.
The Company will promote this standard in all laboratories that license or
utilize our technology.



ATGRAFT™ Adipose Tissue Storage Service - A clinical fat storage solution
allowing physicians to provide their patients with multiple tissue and cell
storage options. The ATGRAFT™ service, through one liposuction procedure allows
individuals to prepare for future cosmetic or regenerative procedures by storing
multiple samples of their own adipose tissue to be returned in the future as a
natural biocompatible filler, or the sample may be further processed to create
cellular therapy applications without the trauma of further liposuctions.
ATGRAFT™ procedures may include breast reconstruction, layered augmentation,
buttocks enhancement or volume corrections of the hands, feet, face and neck
areas that experience significant adipose tissue (fat) volume reduction as we
age. ATGRAFT™ is processed and stored utilizing our standards so that any stored
fat tissue sample may be retrieved in the future and re-processed to create stem
cells "ATCELL™", our clinical grade cell product for use in Regenerative
Medicine applications.



The Company charges standardized fees for ATGRAFT™ tissue processing and a
minimum annual storage fee depending on the volume of tissue stored. These
processing and storage fees may be paid to the Company by the
collecting/treating physician or the consumer. The Company earns additional
fees, for the thawing, packaging and shipment of the stored samples back to the
physician or clinic for immediate use upon receipt. Additionally, physicians or
patients may request that any stored ATGRAFT™ tissue sample of 25ml or greater
be reprocessed utilizing the Company's ATCELL™ and Autokine-CM™ processing. The
Company charges fees for the reprocessing of a 25ml stored ATGRAFT™ sample and
may charge additional fee's if expansion of the newly created ATCELL™ sample is
also requested.



The Company believes the ATGRAFT™ service may create significant revenue
opportunities and patient retention for the participating physician. The
ATGRAFT™ service lowers physician/patient overall costs by eliminating
additional liposuction procedures for each scheduled fat transfer or therapy
procedure. Physician cost savings may include: materials, supplies, equipment,
and the expenses of utilizing a surgical center, hospital operating room or an
in-office aseptic procedure room. The ATGRAFT™ service is designed to operate
under the minimally manipulated regulations contained in both 21 CFR 1271.10 and
PHS 361.



ATCELL™ Adipose Derived Stem Cells (ADSCs) - Clinically processed and
characterized adipose derived regenerative cells (ADRCs) created using the
Company's proprietary Standard Operating Procedures (SOPs) and ACSelerate™
patented cell culture media. ATCELL™ is the Company's trademarked name for its
ADRCs and differentiated cell products and processing methodology. The Company
maintains multiple master and differentiated cell lines and labels them
according to their characterization. (i.e. ATCELL™ (adipose derived stem cells)
ATCELL-SVF™ (stromal vascular fraction), ATCELL-CH™ (differentiated
chondrocytes), etc. Cell lines are custom created for patients desiring to store
their cells for their own use in future Regenerative Medicine procedures. The
Company charges its customers fees to process a previously stored ATGRAFT™
sample and for newly collected client tissue samples to be processed. Customer
samples submitted for processing must utilize the CELLECT® collection system and
ACSelerate™ mediums to conform to our internal SOPs and quality control
standards.

14





The Company's ATCELL™ cell lines are processed and cultured in our patented
ACSelerate™ cell culture media. All tissue, cells, and research materials made
available for sale to research institutions are tested for sterility, disease,
lifespan, and population doubling rate (PDL). Additionally, we believe these
cells are suited for any type of cellular therapy or regenerative medicine
research. Cell morphology is confirmed by (i) flow cytometry and (ii)
differentiation analysis using ACSelerate™ differentiation media. Each ATCELL™
line can be further cultured and differentiated allowing the Company to provide
genetically matched clinical grade cell types. We believe this research
methodology may provide opportunities for the Company's ATCELL™ and ACSelerate™
products to become the building blocks of final developed commercial
applications.



The Company intends to support its cell therapy application research,
development and collaborative efforts by making ATCELL™ and ATGRAFT™ samples
available for research and product development purposes through joint ventures,
and university and commercial collaborations. These adipose tissue and cell line
samples, we believe will be highly sought after by private researchers and
universities for use in pre-clinical trial studies and in-vitro research due to
our clinical processing methodology, donor sample data and the ability to create
multiple cell types that have identical genetic profiles. We believe the
clinical processing methods, data collection and testing of our ATCELL™ and the
ability to make multiple cell types from the same donor line allows research
teams to focus on application development and avoid bench to commercialization
delays. The Company is preparing to distribute its ATCELL™ cell products to
users of its ACSelerate™ cell culture media during 2017. The Company is
investigating new sources of human mesenchymal cell lines for production and
distribution to the cellular therapy research market.



ACSelerate™ Cell Culture Media Products - Manufactured patented cell culture
media products for growing human stromal cells (including all cells found in
human skin, fat and other connective tissue). Certain ACSelerate™ cell culture
media lines are available in animal serum free, which is suitable for human
clinical and therapeutic uses or a low serum version for application development
and research purposes. The patented ACSelerate™ cell culture media line was
specifically developed to address increasing industry demand for animal
serum-free cell culture products and for the acceleration of products from the
laboratory to the patient.



The Company recently entered into a licensing and manufacturing agreement with
PeproTech, Inc a life sciences company formed in 1988. PeproTech is the trusted
source for the development and manufacturing of high quality cytokine products
for the life-science and cell therapy markets.  Over the past 26 years the
company has grown into a global enterprise with state-of-the-art manufacturing
facilities in the US, and offices around the world. With over 2,000 products
PeproTech has developed and refined innovative protocols to ensure quality,
reliability and consistency. During 2016 the Company and PeproTech completed the
optimization and scale up manufacturing studies and expect the licensed medium
marketed under both PeproTech's, PeproGrow™and the Company's ACSelerate-Max™,
brands in 2017. Additionally, the company plans to offer its ATCELL™ research
grade adipose derived stem cells to purchasers of either the PeproGrow™ or
ACSelerate Max™ branded cell culture mediums.



On August 2, 2011, the Company was issued US patent number 7,989,205 for "Cell
Culture Media, Kits and Methods of Use." The granted claims include media
variations for cellular differentiation of ADSCs into osteoblasts (bone),
chondrocytes (cartilage), adipocytes (fat), neural cells, and smooth muscles
cells in both HSA medium (clinical) grade and FBS (research) grade. This patent
covers both non-GMP research grades and GMP clinical grades suitable for cell
culture of adipose-derived stem cells intended for use in humans. Additionally,
in 2014 the Company filed a continuation of this granted patent with additional
claims and improvements, U.S. Serial No. 13/194,900. On November 8, 2016 the
Company was granted additional claims from the continuation U.S. Serial No.
13/194,900 issued as a new Patent Serial No. 9,487,755. Prior to the issuance
the Company filed a continuation in part (CIP) containing additional claims
related to our ongoing media development.



Published cell culture research indicates the most widely used cell culture
medium today for growing and differentiating stem cell cultures for in vitro
diagnostics and research contains fetal bovine serum (FBS) and other animal
derived products. The use of FBS and other animal products in clinical cellular
therapy application development and manufacture raises concerns and generates
debates within the scientific and regulatory community relating to potential
human/animal cross-contamination. These same concerns may lead to additional
expensive and expansive testing and documentation requirements with the FDA
during the application and approval process for new cellular therapies
manufactured with or containing animal or animal derived products. FDA concerns
are evidenced in their Guidance's and Guidelines regarding cellular therapy
involving human cells, tissues and products (HCT/Ps) published and maintained by
the FDA. Management believes that eliminating or greatly reducing FBS in
cellular manufacturing, applications and products can eliminate or ease these
scientific and regulatory concerns and may prove to be a winning strategy for
cellular therapy application developers seeking FDA approval.

15





Our media products are being utilized by our research partners engaged in
developing novel new cellular applications and treatments. The Company supports
these efforts by making ATCELL™ samples available for research purposes and for
internal product development through our research programs. We believe these
cell lines are highly sought after by private researchers and universities for
use in pre-clinical trial studies and in-vitro research. We also believe that
the Company's ability to provide clinical grade materials for these research and
development collaborators, partners and other third parties extends the
Company's ability to become a primary source of clinical grade materials and
services necessary to support approved applications and treatments.



The Company has created several versions of its ACSelerate™ cell culture media including:

· ACSelerate-MAX™ - xeno serum free cell culture media,

· ACSelerate-SFM™ - animal serum free cell culture media,

· ACSelerate-LSM™ - low FBS (0.05%) cell culture media,

· ACSelerate-CY™- for differentiation of ATCELL™ into chondrocytes (ATCELL-CY™),

· ACSelerate-OB™- for differentiation of ATCELL™ into osteoblasts (ATCELL-OB™)

· ACSelerate-AD™ - for differentiation of ATCELL™ into adipocytes (ATCELL-AD™)

· ACSelerate-MY™- for differentiation of ATCELL™ into myocytes (ATCELL-MY™)

· ACSelerate-CP™- non-DMSO (Dimethyl Sulfoxide) cellular cryopreservation media

· ACSelerate- TR™ - sterile transportation medium designed to maintain the

        viability of the tissue during the shipment of adipose tissue to our
        processing facility.




The Company continues to optimize additional versions of ACSelerate™ media
through further research and testing to develop medium versions for
differentiation of ATCELL™ ADSCs into neural, lung and other specific cell types
that may be necessary for use in future clinical applications. On December 31,
2014 the Company filed a patent application for an advanced medium formulation
titled Human Albumin Serum for Cell Culture Medium for Clinical Growth of Human
Adipose Stromal Cells. (US Serial No. 62/098799). On December 31, 2015, the
Company converted the provisional application to an international PCT filing
(PCT/US/68350) under the title Human Serum for Cell Culture for Clinical Growth
of Human Adipose Stromal Cells.



ACS Laboratories™: Laboratory Product Sales, Contract Manufacturing and
Professional Services - ACS Laboratories is a division of American CryoStem
Corporation, responsible for the manufacturing and sale of all the Company's
patented and patent pending cellular, cell culture, processing and testing
products to professional, institutional and commercial clients. The Company
operates a separate website (acslaboratories.com) to distinguish the sale of
commercial and research products from its consumer products and services, which
are marketed on its main website (americancryostem.com). ACS Laboratories
manufactures a full line of ACSelerate™ cell culture media and ATCELL™ products;
and provides these products to our collaborative partners and international
licensees as further discussed below.



Contract Manufacturing, Autokine-CM® Anti-Aging, Autologous Skin Care Product
Line - Under agreement with Personal Cell Sciences Corp. (PCS), we manufacture
the key ingredient Autokine-CM® (autologous adipose derived stem cell
conditioned medium) for PCS' U-Autologous™ anti-aging topical formulation. Each
product is genetically unique to the individual and custom blended, deriving its
key ingredients from the individual client's own stem cells. The Company
provides its CELLECT® Tissue Collection service to collect the required tissue
to manufacture the U-Autologous™ product and processes it under the same
Standard Operating Procedures that it developed for the ATGRAFT™ and ATCELL™
cell processing services utilizing ACSelerate™ cell culture media. The Company
receives collection, processing and long term storage fees and earns a royalty
on all U-Autologous product sales. The utilization of the Company's core
services in its contract manufacturing relationships provides opportunities for
the Company to promote ATGRAFT™ and ATCELL™ products.



Our Company's contract manufacturing services can be extended to develop custom
and/or white label products and services for both local and global cosmetic and
regenerative medicine companies, physicians, wellness clinics and medical spas.
The Company intends to expand its relationships and contract manufacturing
regionally through its physician networks and globally through its International
Licensing Program.

16





International Licensing Program - The Company believes that many jurisdictions
outside the US currently permit use of cellular therapies and regenerative
medicine applications. The Company has received international inquiries
concerning the sale or licensing of our SOPs, products and services in the
Regenerative Medicine and Medical Tourism Markets. The Company believes that the
inquiries to date are a result of the global boom in Medical Tourism,
Regenerative Medicine and the slow pace of approval of cellular therapies and
regenerative medicine applications in the US. To address the Company's sales,
marketing and branding opportunities globally, the Company has created its
international licensing program. To date we have licensed our technologies in
Hong Kong, Shenzhen, China and, Tokyo, Japan.



The Company believes it can take advantage of the significant growth of the
global cellular therapy market through its international licensing and marketing
efforts. A recently published study by Transparency Market Research predicts
that the Stem Cell market will grow at a CAGR of 24.2% upon its value of US
$26.23 billion in 2013 and will reach an approximate value of US $119.52 billion
by 2019. The report, titled "Stem Cells Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast, 2012 - 2018"; which can be found at
(http://globenewswire.com/news-release/2014/12/22/693419/10113247/en/Global-Stem-Cells-Market-to-grow-at-a-CAGR-of-24-2-to-Push-US-119-52-billion-by-2019-Transparency-Market-Research




In June of 2015, The Company entered into an initial agreement with CellSource,
LTD. ("CellSource") located in Shibuya, Tokyo Japan for the licensing of our
AGRAFT™ tissue processing and storage technology and the purchase of our
CELLECT® collection products which include our ACSelerate-TR™ transport medium.
The Company also assisted TCCS in upgrading its facility in Japan and provided
training in ATGRAFT™ processing and laboratory recordkeeping procedures.
CellSource began marketing the new services initially within its existing
network of 5 clinics throughout Japan and begin purchasing its CELLECT™ and
ACSelerate-CP™ cryoprotectant from the Company in the third quarter of 2015.
Upon execution of the Agreement the Company received an upfront payment and will
receive additional minimum annual payments, and consumable product sales revenue
in future years. The Agreement also provided CellSource with a two year (2)
opportunity to exercise a right of first refusal for the licensing and
distribution of other products marketed by the Company in Japan.



Product Development



Our strategic approach to product development is to design, develop and launch
new products and services that utilize our existing products and services, i.e.
the use of the CELLECT® collection materials in providing ATGRAFT™ tissue
storage services. Management believes that this approach will provide the
Company with opportunities to produce near term cash flow, strong recurring
revenue streams, strong international licensing partners and complementary
scientific data. We focus on developing products, services and applications that
require tissue collection and processing as the initial requirement to produce
cellular therapies and products. These products and services may include adipose
tissue and stem cell sample processing and storage as a form of personal
"bio-insurance", adipose tissue (fat) storage for cosmetic fat engraftment
procedures, and the creation and production of topical applications and
ingredients used by other companies in the wound care and cosmetic industries as
well as cellular applications and bio-materials development.



We intend to focus our efforts on expanding our products and services pipelines
based upon our intellectual property portfolio, collaborative development
relationships, product sales and distribution, and international licensing and
partnering opportunities. Our current activities include supporting our
university and industry collaborations by providing our products and services
with the expectation that our products and services become the basis for new
adipose tissue and stem cell based Regenerative Medicine and cellular therapy
applications. We believe this strategy allows our proposed research partners and
their application development teams to begin with clinically harvested and
processed adipose tissue and ADSCs (ATCELL™), which may be a significant step
toward accelerating the development and approval of new treatments.

17




Collaboration / Partnering Opportunities / Acquisitions

PeproTech, Inc.


On April 4, 2016 the Company entered into an Agreement with PeproTech, Inc of
Rocky Hill, NJ. Under the Agreement PeproTech will manufacture, market and
distribute the Company's ACSelerate-Max cell growth medium. During 2016 the
Company and PeproTech completed the optimization and scale up manufacturing
studies and expect licensed medium marketed under both PeproTech's PeproGrow and
the Company's ACSelerate-Max brands in early 2017. PeproTech will leverage its
current global sales relationships which reach a majority of all research
laboratories worldwide to maximize distribution of ACSelerate-Max and other
optimized media lines Additionally, the Company and PeproTech are discussing the
licensing of additional American CryoStem patented media and products for
production and distribution by PeproTech, any additional media licensed to
PeproTech will undergo similar optimization and scale up production testing
prior to being released for sale.

In January 2017 the first medium line ACSelerate Max™ was manufactured and
released for sale globally through PeproTech's global sales force under their
PeproGrow™ brand and for sale by the Company under our ACSelerate-Max™ brand.

Customer and Physician Acquisition


In February 2015 the Company entered into a binding asset purchase agreement
with BioLife Cell Bank Dallas, LLC and BioLife Cell Bank Management, LLC
(collectively "BioLife"), to purchase all of BioLife's adipose tissue, stem cell
storage clients samples, and physician network. The transaction was concluded in
March of 2015. Transfer of the adipose tissue samples was completed on April 24,
2015 and the Company undertook a complete physical inventory of the transferred
samples. The Company initiated annual storage fee billing to the acquired
storage clients in June of 2015. Management believes that, with the acquisition
of BioLife, the Company became one of the largest commercial adipose tissue
storage facility in the United States.

Protein Genomics and Formation of Autogenesis Corporation


In 2012, American CryoStem entered into a Memorandum of Understanding (MOU)
outlining our initial collaborative efforts with Protein Genomics, Inc. (PGEN)
to test and develop new products by combining certain components of our
respective intellectual property and patented products. We have provided PGEN
and its research partner, Development Engineering Sciences (DES), with Adipose
Derived Stem Cells (ATCELL™) and our patented cell culture mediums (ACSelerate™)
for testing with PGEN's products designed for the wound healing market. Research
and development has been ongoing since late 2012 and notable progress has been
achieved.

As a result of the success realized in the early stage of this research
collaboration, in fiscal 2013 we entered into a formal joint venture with
Protein Genomics through the incorporation of Autogenesis, Corp. as required by
the 2012 MOU. Each company (CRYO and PGen) initially has an equal ownership
interest. All products capable of being commercialized, as well as any new
intellectual property, resulting from the ongoing scientific collaboration will
be wholly-owned by Autogenesis. This is representative of how we believe
additional research collaborations utilizing our Company's technology may evolve
in the future.

During 2013 and 2014, the collaborative efforts resulted in successful initial
"proof of concept" combining PGEN's unique biomaterial and the Company's ATCELL™
and ACSelerate™ products. Management believes the publication of the preliminary
results showed successful healing of full depth wounds on the backs of immune
deficient mice.

Our collaborative research has established that membrane scaffolds fabricated
from human proteins can be cultivated with ATCELL™ cells causing the scaffolds
to be rapidly and completely covered by the cells. The cells then secrete their
own extracellular matrix, creating a structure with layers of matrix, cells and
scaffold. This living structure, when introduced into a mouse wound model,
localizes the stem cells in the wound, protects the cells within the wound
environment, promotes cell growth and causes a statistically significant
increase in the rate of wound closure and healing compared to the standard of
care.  Further evaluation will measure the performance of these scaffolds in
accelerating the rate of wound closure, healed scar thickness, growth of new
blood vessels and production of key wound healing factors. Our objective is to
show that these constructs can stimulate the growth of new tissue and promote
wound closure and healing.

18





Cells on Ice:

In August of 2015 the Company entered into an Agreement with Cells On Ice, Inc.
(COI) located in Los Angeles, California to process and cryopreserve adipose
tissue and adipose derived cellular samples for future use in Regenerative
Medicine. COI is a network of physicians interested in the development and use
of adipose tissue and adipose derived cellular samples in regenerative therapies
and cellular medicine. The Company has agreed to distribute its CELLECT®
collection boxes and provide its ATGRAFT™ and ATCELL™ processing services for
the collection, processing and storage of tissue samples at its NJ facility.
Under the agreement, COI will pay the Company for the processing and storage of
each sample generated by COI network physicians. COI plans to seek regulatory
approval for use of the stored samples in clinical studies utilizing adipose
tissue processed into Stromal Vascular Fraction (SVF) and ultimately expanded
adipose derived mesenchymal adult stem cells. The Company is incorporating its
existing Standard Operating Procedures (SOPs), processing protocols and patented
products into COI's studies and may provide processing and other data to COI in
support of their ongoing efforts to develop and obtain regulatory approval of
its cellular therapies. COI has initiated several IRB approved studies including
a recently completed transportation study approved in August of 2016 to measure
the survivability of cell samples shipped in a newly developed return transport
medium, animal studies for traumatic brain injury approved in September of 2016,
and the safety of intravenously delivered autologous ATCELL™ products approved
in October of 2016. This initial work will become the basis for a series of
regulatory filings with the FDA in 2017.

Additional Collaborations


The Company is in the early stages of developing collaborations with additional
industry and university partners. These developing relationships in their
earliest stages are covered by Confidential Disclosure Agreements and those that
are more advanced also include Material Transfer Agreements under which the
Company supplies either ATCELL™ or ACSelerate™ medium products for evaluation,
testing, and the development of new cellular therapy applications.

To date the Company has a Material Transfer Agreement with the University of
Miami, University of Washington, UHV Technologies, and STEMCell Technologies and
has provided both ATCELL™ and ACSelerate™ products to these entities under
Agreement. No assurance can be given that these relationships will progress to
full collaborative agreements or ultimately result in new technology for future
commercialization. As of December 31, 2016 these relationships have yet to
result in a commercial product.

In August of 2015 the Company entered into a Confidential Disclosure Agreement
and a Material Transfer Agreement with Dr. Sazlay, a research scientist
currently investigating unique cancer treatments at the University of Wurzburg
in Germany and the University of California in San Diego. Following execution of
the Agreement, the Company delivered a number of ATCELL-SVF™, ATCELL™ and
ACSelerate™ samples to Dr. Sazlay for testing and determination of usefulness of
our products for development of his novel treatments. Dr. Sazlay has reported
positive results of this initial work and the Company and Dr. Sazlay have been
unable to reach an agreement to further our relationship to date.

19





Intellectual Property



From the Company's formation, our strategy has been to invest time and capital
in intellectual property protection. This strategy is intended to strengthen our
Company's foundation in any defensive or offensive legal challenge. In addition,
we are developing our IP portfolio to ensure and enhance our business
flexibility and allow us to gain favorable terms in potential future
collaborative partnerships with third parties. Our intellectual property
portfolio currently includes one issued U.S. patent (No. 7989205, Cell Culture
Media Kits and Methods of Use); and five pending patent applications which are
detailed in the following chart:

              PATENT TITLE                            APPLICATION #
A Business Method for "Collection,       U.S. Serial No. 13/702,304 filed June 6,
Cryogenic Storage and Distribution of a  2011, and claiming a priority date of
Biological Sample Material"              June 7, 2010 from provisional
                                         application 61/352,217
Systems and Methods for "The Digestion   U.S. Serial No. 13/646,647 filed October
of Adipose Tissue Samples Obtained From  5, 2012, and claiming a priority date of
a Client for Cryopreservation"           October 6, 2011 from provisional
                                         application 61/544,103
Compositions and Methods for
"Collecting, Washing, Cyroprocessing,    PCT/US13/44621 Filed June 6, 2013 and
Recovering and Return of Lipoaspirate to claiming a priority date of June 7, 2012Physicians for Autologous Adipose
Transfer Procedures"
                                         U. S. Serial No. 14/196,616 filed 

March

Stem Cell-Based Therapeutic Devices and 4, 2014 and claiming a priority date Methods

                                  from provisional application 

61/773,112

                                         filed March 5, 2013

Autologous Serum for Transport of U.S. Serial No. 14,250,338 and claiming Isolated Stromal Vascular Fraction or a priority date from provisional Adipose Derived Stem Cells

               application 61/810,970 filed April 

11,

                                         2013
Cell Culture Media, Kits, and Methods of U.S. Serial No. 13/194,900
Use
Human Serum for Cell Culture Medium for
Clinical Growth of Human Adipose Stromal PCT/US/68350 Filed December 31, 2015
Cells
Systems and Methods to isolate and       Provisional Patent Application No.
Expand Stem Cells from Urine             62/335,426




Additionally, the Company has in-licensed IP with the following collaborations
and joint ventures;



              PATENT TITLE                            APPLICATION #

Cosmetic compositions including USPTO #5,726,040 tropoelastin isomorphs Cosmetic compositions

                    USPTO #6,451,326
Recombinant hair treatment compositions  USPTO #6,572,845
Wound healing compositions and methods   USPTO: #6,808,707
using tropoelastin and lysyl oxidase
Business methods, processes and systems
for collection, cryogenic storage and
distribution of cosmetic formulations    USPTO application #61/588,841
from an obtained stem cell
based biological


20





Trademarks

In addition to patents, the Company has registered the following trademarks with
the U.S. Patent and Trademark Office: American CryoStem®, CELLECT® and ATGRAFT™.
We utilize additional trademarks for our products, slogans and themes to be used
in our marketing initiatives, including, for example, ACSelerate - MAX SFM™
ACSelerate-SFM™, ACSelerate- LSM™ and ATCELL™.



The Company has also secured a number of online domain names relevant to its business, including www.americancryostem.com, www.acslaboratories.com and ATGRAFT.com.




Marketing and Distribution



The key objective of our marketing strategy is to position American CryoStem in
the market as the "Gold Standard" for adipose tissue collection, cell processing
and cryogenic storage, therapeutic applications, and research/commercial uses of
adipose tissue within the current regulatory framework. The combination of a
traditional sales approach supported by continuous internal and external
marketing programs, are closely coordinated with the expansion of our laboratory
processing capabilities. Our initial marketing efforts intend to disseminate
current and future uses of adipose tissue and adult stem cells which support our
business model, products and services. In 2017, we intend to continue to employ
both print advertising and social media sales campaigns. In addition, we plan to
continue to utilize key leaders, and early adopters in the medical community as
a marketing resource to enhance awareness of our proprietary, patented products
and services and to increase the number of surgeons who join our network,
university and private collaboration and consumers who use our products and
services.



We plan to continue direct marketing programs focused on reaching plastic and
cosmetic surgeons to join the initial group of providers that began to offer our
services to their patients in 2015. This marketing initiative has been
implemented using a traditional sales approach common to the pharmaceutical and
biotechnology industries. This fundamental sales approach at the core of our
marketing activities is being strategically and tactically expanded using a
combination of in-house sales personnel and outside independent channels.



Our plan, capital permitting, provides for a comprehensive integrated marketing
approach using various traditional and new media, such as the Internet, social
media/blogging, video, print, TV, radio and trade shows to reach targeted
potential consumers and promote awareness of our Company and our branded
products and services. The essence of this targeted strategy is to reach the
end-users as quickly as possible and to accelerate the adoption curve of our
products and services. We also plan to utilize outside marketing resources and
trade groups to increase the number of surgeons willing to offer our products
and services to their patients.



Market Size and Opportunities


By leveraging and capitalizing on our proprietary Adipose Tissue Processing
Platform, we are working to address multiple high growth, multi-billion dollar
market opportunities, including those prevailing within the Regenerative
Medicine, Cosmeceuticals, Medical Tourism and Cell Culture Media markets. The
Company regularly reviews independent market research to gauge the market
dynamics of its intended domestic and international markets and to identify
additional areas within these markets where the Company's cell culture medium,
laboratory products, and tissue and cellular processing services, can be
marketed, sold and/or licensed.

21





Global Stem Cells Market



A report from Transparency Market Research (TMR) forecasts that the  global stem
cells market  will grow at a remarkable CAGR of 24.2% from 2012 to 2018.
According to TMR, a market intelligence firm, the global stem cells market,
which in 2013 stood at US$26.23 bn, is anticipated to reach US$119.52 bn by the
end of the forecast period. The report, titled 'Stem Cells Market - Global
Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018',
http://www.transparencymarketresearch.com/pressrelease/stem-cells-market.htm



A report published by Markets and Markets Research in July 2014 titled "Cell
Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent
(Media, Sera, Growth Factors, Serum Free Media), by Application (Cancer
Research, Gene Therapy, Drug Development, Vaccine Production, Toxicity Testing)
- Global Forecast to 2018" July 2014.
(http://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html)



The report states that "The global cell culture market was valued at $ 14,772
million in 2013 and is poised to grow at a CAGR of 10.71% between 2013 and 2018,
to reach $24,574 million in 2018. Rapid increase in biopharmaceutical production
and increasing healthcare expenditure will be the two most important growth
drivers for this market in the forecast period from 2013 to 2018.
Biopharmaceutical production had the largest share of the cell culture market in
2013. According to IMS Health, biopharmaceutical is expected to one of the
fastest growing pharmaceutical segment between 2012 and 2017. The increasing
demand for biopharmaceutical products like vaccines and antibodies coupled with
strong pipelines for biopharmaceuticals and increasing healthcare expenditure
will drive the demand for cell culture products."



Another report by Transparency Market Research titled "Stem Cells Market -
Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018"
states "The Global Stem Cells Market to grow at a CAGR of 24.2%, to Push
US$119.52 billion by 2019. The report analyzes the highly fragmented stem cells
market by the type of stem cells, processes in the stem cell market,
applications of stem cells, and geography. Regenerative medicine is by far the
dominant application of stem cells, including uses in neurology, cardiology, and
oncology. According to process, the market is divided into the stem cell
acquisition, stem cell production, stem cell cryopreservation, and stem cell
expansion segments. Due to the expected increase in demand, stem cell
acquisition will retain its position as the major segment of the stem cell
market. Geographically, North America and Europe will remain well ahead of the
competition."


(http://globenewswire.com/news-release/2014/12/22/693419/10113247/en/Global-Stem-Cells-Market-to-grow-at-a-CAGR-of-24-2-to-Push-US-119-52-billion-by-2019-Transparency-Market-Research.html#sthash.4vzqG1wc.dpuf)


Regenerative Medicine Market



According to a leading research firm focused on the biotechnology, healthcare
and life sciences industries, TriMark Publications categorizes the Regenerative
Medicine market into three main categories:



 · Tissue Engineering;


 · Biomaterials; and

· Biomolecules (scaffolds, growth factors and stem cell therapy).


22





TriMark Publications.com cites in its "Regenerative Medicine Markets" report
(March 2013) that the Regenerative Medicine market continues to witness
significant advances in clinical efficacy, regulatory approval and product
commercialization of cell based therapies which will catapult to over $35
billion by 2019. Affirmative results produced from the application of adult stem
cells have resulted in greater government and private sector investment in
research and development of new cell therapies. Investment made into the
regenerative medicine market include firms that harvest, process, purify,
expand, cryopreserve, store or administer stem cells"1 In a study from Market
Research Reports, released "Global Regenerative Medicine Market (Technology,
Applications, Geography) - Industry Analysis, Trends, Opportunities and
Forecast, 2013-2020." In it, the market analysis firm found the  global
regenerative medicine market will be worth some $67.6 billion by 2020 - a stark
and notable increase from the $16.4 billion valuation it received in 2013.
Between 2014 and 2020, the report expects the regenerative medicine market to
grow at a compounded annual growth rate of 23.2 percent.



According to Allied Market Research, on the basis of geography, this market can
be classified into North America, Europe, Asia-Pacific and LAMEA. Currently,
North America dominates the global market due to heavy investment in development
of regenerative products as well as more number of commercialized products.
However, the growing focus on research and development in Japan and South Korea
makes Asia-Pacific the fastest growing region at a CAGR of 30.9% during
2014-2020.



Medical Tourism, Global Wellness Tourism




As stated by the Global Wellness Institute; adding up all expenditures made by
international/inbound and domestic, primary and secondary wellness tourists, we
estimate the wellness tourism industry to be $494 billion in 2013, a 12.7%
increase over 2012. Wellness tourism accounts for 14.6% of all tourism
expenditures and is growing much faster than the 7.3% growth rate for overall
tourism expenditures from 2012-2013. The $494 billion in wellness tourism
expenditures represent 586.5 million wellness trips taken in 2013, across 211
countries. Wellness tourism accounts for about 6.2% of all domestic and
international tourism trips taken in 2013.

http://www.globalwellnesssummit.com/images/stories/gsws2014/pdf/GWI_Global_Spa_and_Wellness_Economy_Monitor_Full_Report_Final.pdf

Cell Culture Market


The Company believes the reproducibility of scientific studies has become a
substantial issue in life science research from drug discovery and development
through clinical trials as researchers throughout the world continue to use
different protocols for processes associated with sample preparation,
cryopreservation and cold chain management. We believe the scientific community
is becoming more aware of factors that affect sample integrity and experiment
variability. By standardizing handling, storage, and transportation protocols we
believe we can substantially improve the quality and reproducibility of
preclinical and clinical data which we believe will help to accelerate the
transition from lab research to drug development and market launch.



According to MarketsandMarkets, "the global cell culture market was valued at an
estimated $14,772 million in 2013. This market is expected to grow at a CAGR of
10.71% between 2013 and 2018, to reach $24,574 million in 2018. The cell culture
media, sera, and reagents market consists of six segments, namely, contamination
detection kits, cryoprotective agents, lab reagents, media, serum, and other
reagents. Of these, the serum product segment had the largest share of the cell
culture media, sera, and reagents market in 2013, whereas the media product
segment is expected to grow at the highest CAGR between 2013 and 2018."



Cosmeceutical Market



Many industry experts agree that Cosmeceuticals has become one of the fastest
growing segments of the Cosmetics and Personal Care industry. Cosmeceutical
products have a big emphasis on scientifically advanced formulations and often
contain active ingredients that can also be found in pharmaceutical products.
This continued emergence of increasingly sophisticated active ingredients is
said to be the main driving force behind the growth of this segment, which is
rapidly evolving into significant category of the personal care industry.





1 http://www.trimarkpublications.com/regenerative-medicine-markets/

23





In a report titled Global Cosmeceuticals Market Outlook 2016, published February
2013, RNCOS reports that the worldwide market is estimated to be valued at $30.5
billion and is likely to grow at a consistent CAGR of 7.7% during the period
2012 through 2016.2 In a separate report, Transparency Market Research, a U.S. -
based market intelligence firm states that the global facial care market is
expected to report an approximate value of $39.75 billion by 2019. The report,
titled 'Facial Care Market (By Product Type - Skin Whitening/ Lightening and
Anti-Ageing, Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks and
Others (fade creams, pore strips and toners)- Asia-Pacific Industry Analysis,
Size, Share, Growth, Trends and Forecast 2013 - 2019.
http://globenewswire.com/news-release/2014/10/17/674123/10103135/en/Global-Facial-Care-Market-to-be-Worth-39-75-Billion-by-the-year-2019-Transparency-Market-Research.html



Development of U.S. Markets

Cells on Ice

In August of 2015 the Company entered into an Agreement with Cells On Ice, Inc.
(COI) located in Los Angeles, California to process adipose tissue and adipose
derived cellular samples for future use in Regenerative Medicine. COI is a
network of physicians interested in the development and use of adipose tissue
and adipose derived cellular samples in regenerative therapies and cellular
medicine. The Company has agreed to distribute its CELLECT® collection boxes and
provide its ATGRAFT™and ATCELL™ processing services for the collection,
processing and storage of tissue samples at its NJ facility. Under the
agreement, COI will pay the Company for the processing and storage of each
sample generated by COI network physicians. COI plans to seek regulatory
approval for use of the stored samples in clinical studies and trials utilizing
adipose tissue processed into Stromal Vascular Fraction (SVF) and ultimately
expanded adipose derived mesenchymal adult stem cells. The Company is
incorporating its Standard Operating Procedures (SOPs), processing protocols and
products into COI's studies and providing processing and other data to COI in
support of their ongoing efforts to develop and obtain regulatory approval of
its cellular therapies.

Physician Network

The Company continues to develop relationships to leverage our products and
services through existing cosmetic surgery and regenerative medicine practices
while at the same time growing its current efforts to develop and expand its
network of individual physicians and surgeons seeking to adopt the Company's
products and services. These efforts are currently focused on surgeons
performing liposuction, tissue transfer or regenerative procedures involving the
use of adipose tissue. The Company intends to expand its efforts to non-cosmetic
medical professionals interested in Regenerative Medicine applications utilizing
ADSCs to establish itself as a primary source of collection, processing and
preparation of cellular therapies as they are developed and approved for patient
use by the FDA.


Regenerative Medicine Institute




The Company recently announced that Dr. Vincent Giampapa, MD F.A.C.S has joined
its Medical and Scientific Advisory Board. Dr. Giampapa is the founder /director
of the Regenerative Medicine Institute (RMI) located in Costa Rica and the US,
the Plastic Surgery Center International and The Giampapa Institute for
Anti-Aging Medical Therapy located in Montclair, NJ. Dr. Giampapa's research
focuses on stem cell technologies and their clinical applications to improve the
cellular aging process in order to enhance health span and quality of life. As a
result of his research, Dr. Giampapa has been awarded medical and intellectual
property patents with the United States Patent and Trademark Office for
developments involving unique cell culture delivery techniques, new drug
delivery systems, stem cell reprogramming, DNA repair, and telomerase
maintenance. He is a co-founder of The Academy of Anti-Aging Medicine (A4M),
comprised of over 26,000 members representing over 110 nations, the first
president of the Board of Anti-Aging Medicine and the founder of healthycell®,
an advanced cell health nutritional supplement and StemBank™, a blood derived
stem cell extraction and storage company. Dr. Giampapa will have an active role
assisting the Company with the development of its "From laboratory to
clinic/physician's office" services and applications platform.





2 http://www.researchandmarkets.com/research/mbmvbh/global

24




Development of International Markets




International Licensing Program - Globally, many jurisdictions outside the US
permit the use of adipose tissue, cellular therapies and regenerative medicine
applications. The Company has received numerous inquiries concerning the sale or
licensing of our products and services in these jurisdictions. The Company
believes that the inquiries to date are a result of the global boom in Medical
Tourism and the slow pace of approval of cellular therapies and regenerative
medicine applications in the US. To address these inquiries and to expand the
Company's sales, marketing and branding opportunities the Company has designed
and is offering an International Licensing Program.

The program is designed to permit the licensing of the Company's products and
services to organizations that meet the Company's financial and technical
criteria. The licensing program allows for a variety of business relationship
including franchising, partnering and joint venturing. Marketing efforts to date
have been to clinics, physician and hospitals in foreign jurisdictions capable
of rapidly building or committing the appropriate facilities and personnel to
create the required laboratory facilities to operate the CELLECT®, ATGRAFT™ and
ATCELL™ services in their local market. Strategically, the Company's
international licensees will maintain the branding of the Company's services
along the lines of the "Intel Inside" branding program.

Qualified Licensees can quickly take advantage of the rapidly expanding
opportunity to collect, process, store and culture individual stem cell samples
for their clients with the comfort and confidence that they are providing
services that have been developed to US FDA standards. Core to the relationship
is the developed proprietary and patent pending processing and laboratory
operational methodologies contained in our Standard Operating Procedures (SOPs),
Training, and Continuous Quality Management, Testing Program, and Laboratory
Operations manuals.

Licensing programs may be initiated through a letter of intent (LOI) agreement
between the Company and the prospective licensee. This LOI agreement is designed
for due diligence and facility qualifications purposes. The Company may receive
an initial fee under the agreement which is credited toward future royalty
payments. Following evaluation of the prospective licensee the Company will
enter into a final Agreement which outlines all upfront fees, minimum royalties
and consumable purchase obligations of the Licensee. The Company's first
international licensing agreement was executed with Health Innovative Technology
Company, LTD, a cord blood collection and storage company with operations in
Hong Kong and Shenzhen China in 2014.



We have committed extensive resources to establishing and perfecting our
international shipping methodologies and protocols, ensuring that our processes
meet the highest possible standards of regulatory compliance for shipment of
biologic materials. As a result, our FDA registered laboratory and cryostorage
facilities in New Jersey are now able to send and receive viable tissue samples
to and from clients globally.


CellSource, LTD. - Tokyo, Japan




On June 2, 2015 the Company and Cell Source Ltd entered into an Agreement for
licensing the ATGRAFT™ technology to Cell Source Ltd. for the country of Japan.
The Agreement calls for Cell Source Ltd. to purchase consumables from us
including the CELLECT® collection boxes and ACSelerate™ Cryopreservation Medium.
The agreement also provides Cell Source with a twenty four month limited Right
of First Refusal for licensing additional technologies from the Company for the
Japanese market. According to Allied Market Research, World Regenerative
Medicines Market Currently, North America dominates the global Regenerative
Medicine market due to heavy investment in development of regenerative products
as well as more number of commercialized products. However, the growing focus on
research and development in Japan and South Korea makes Asia-Pacific the fastest
growing region at a CAGR of 30.9% during 2014-2020. During 2017 CellSource began
testing our ACSelerate Max cell culture medium.

25




Health Information Technology Company, LTD - Hong Kong and Shenzhen, China


On June 30, 2014 the Company granted Health Information Technology Company, LTD
("HIT") exclusive rights to utilize the Company's Standard Operating Procedures
(SOP's) to market the Company's ATGRAFT™ tissue storage service in Hong Kong.
The Agreement calls for upfront fees, royalties and the purchase by HIT of
certain consumables manufactured by the Company. The Company and HIT have
reached further agreement to extend their relationship on a non exclusive basis
to include HIT's cord blood laboratory located in Shenzhen, Guangdong Province,
one of China's most successful Special Economic Zones. The HIT agreement
includes, initial upfront fees and royalty payments for predetermined gross
revenue volumes. HIT will also purchase CRYO ACSelerate™ storage media, CELLECT™
collection and transportation kit as well as other American CryoStem products
necessary for clinical adipose tissue processing and storage at the Shenzhen
cord blood collection facility. The final master licensing agreement is for a
period of 5 years with renewal options and was executed between the parties on
September 24, 2014.



Corporate Information



Our principal executive offices are located at 1 Meridian Road, Eatontown, New
Jersey 07724 and our telephone number is (732) 747-1007 our fax number is
732-747-7782. Our website is www.americancryostem.com We also lease and operate
a tissue processing laboratory in Monmouth Junction, New Jersey at 7 Deer Park
Rd, Monmouth Junction, NJ. 08852. Our laboratory website address is
www.acslaboratories.com.



Available Information

We file electronically with the U.S. Securities and Exchange Commission (SEC)
our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports
on Form 8-K, and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of 1934. The public can
obtain materials that we file with the SEC through the SEC's website at
http://www.sec.gov or at the SEC'sPublic Reference Room at 100 F Street, NE,
Washington, DC 20549. Information on the operation of the Public Reference Room
is available by calling the SEC at 800-SEC-0330.



Going Concern



As of the date of this quarterly report, there is substantial doubt regarding
our ability to continue as a going concern as we have not generated sufficient
cash flow to fund our business.



We have suffered recurring losses from operations since our inception. In
addition, we have yet to generate sufficient internal cash flow from our
business operations or successfully raise the financing required to fully
develop our business. As a result of these and other factors, our independent
auditor has expressed substantial doubt about our ability to continue as a going
concern. Our future success and viability, therefore, are dependent upon our
ability to generate capital financing. The failure to generate sufficient
revenues or raise additional capital may have a material and adverse effect upon
us and our shareholders.



Our plans with regard to these matters encompass the following actions: (i)
obtaining funding from new investors to alleviate our working capital
deficiency, and (ii) implementing a plan to generate sales of our proposed
products and services. Our continued existence is dependent upon our ability to
resolve our liquidity problems and increase profitability in our current
business operations. However, the outcome of management's plans cannot be
ascertained with any degree of certainty. Our financial statements do not
include any adjustments that might result from the outcome of these risks and
uncertainties.


Liquidity and Capital Resources




We had a cash balance of $91,494, the date of this quarterly report. Should we
be unable to raise sufficient funds, we will be required to curtail our
operating plans if not cease them entirely. We cannot assure you that we will
generate the necessary funding to operate or develop our business. Please see
"Cash Requirements" above for our existing plans with respect to raising the
capital we believe will be required.

26





In the event that we are able to obtain the necessary financing to move forward
with our business plan, we expect that our expenses will increase significantly
as we attempt to grow our business. Accordingly, the above estimates for the
financing required may not be accurate and must be considered in light these
circumstances.



Cash Requirements



We will require additional capital to fund marketing, operational expansion,
processing staff training, as well as for working capital. We are attempting to
raise sufficient funds would enable us to satisfy our cash requirements for a
period of the next twelve (12) to twenty-four (24) months. We have minimal long
term debt and have been able to meet our past financial obligations.



In order to finance further market development with the associated expansion of
operational capabilities for the time period discussed above we are planning
additional fundraising through the sale of our equity and debt securities
however we cannot assure you we can attract sufficient capital to enable us to
fully fund our anticipated cash requirements during this period. In addition, we
cannot assure you that the requisite financing, whether over the short or long
term, will be raised within the necessary time frame or on terms acceptable to
us, if at all. Should we be unable to raise sufficient funds we may be required
to curtail our operating plans if not cease them entirely. As a result, we
cannot assure you that we will be able to operate profitably on a consistent
basis, or at all, in the future.



We expended $13,794 during the three months ended June 30, 2017 in professional fees (legal, accounting and consultants) and $61,435 in Laboratory expenses



Commitments



The Company is committed to a non-cancelable lease for lab space in South
Brunswick, New Jersey through fiscal year 2019. Minimum lease payments under
this lease are as follows:



                      2017                           $ 19,536
                      2018                             39,072
                      2019                             13,024
                      Net minimum lease payments     $ 71,632

The Company also leases office space in Eatontown, New Jersey. The lease is on a "month to month" basis and rents for $2,650 per month.

The Company is not party to any litigation against it and is not aware of any litigation contemplated against it as of June 30, 2017.




We anticipate that any further capital commitments that may be incurred will be
financed principally through the issuance of our securities. However, we cannot
assure you that additional financing will be available to us on a timely basis,
on acceptable terms, or at all.



Related Party Transactions



At June 30, 2017, the Company has a note receivable from Autogenesis, discussed
in Note 12, for $31,039. The note receivable has no interest rate, is unsecured,
and due on demand.


At June 30, 2017, the company was indebted to a Company that is the majority owner of the Company for $108,820. The advances are due on demand, are unsecured, and carry no interest rate.




At June 30, 2017, the company was indebted to a Company that is majority owned
by one Company's chief executive officers for $7,540. The advances are due on
demand, are unsecured, and carry no interest rate.

27




Off Balance Sheet Arrangements




We have no off-balance sheet arrangements that have or are reasonably likely to
have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources that are material to investors.



Critical Accounting Policies



We prepare financial statements in conformity with U.S. generally accepted
accounting principles ("GAAP"), which requires us to make estimates and
assumptions that affect the amounts reported in our combined and consolidated
financial statements and related notes. We periodically evaluate these estimates
and assumptions based on the most recently available information, our own
historical experience and various other assumptions that we believe are
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Since the use of estimates is an
integral component of the financial reporting process, actual results could
differ from those estimates. Some of our accounting policies require higher
degrees of judgment than others in their application. We believe the following
accounting policies involve the most significant judgments and estimates used in
the preparation of our financial statements.



Basis of Presentation



Our financial statements are presented on the accrual basis of accounting in
accordance with generally accepted accounting principles in the United State of
America, whereby revenues are recognized in the period earned and expenses when
incurred.


Management's Use of Estimates




The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting periods. Actual results
could differ from those estimates.



Long-Lived Assets



We review and evaluate our long-lived assets for impairment whenever events or
changes in circumstances indicate that their net book value may not be
recoverable. When such factors and circumstances exist, we compare the assets'
carrying amounts against the estimated undiscounted cash flows to be generated
by those assets over their estimated useful lives. If the carrying amounts are
greater than the undiscounted cash flows, the fair values of those assets are
estimated by discounting the projected cash flows. Any excess of the carrying
amounts over the fair values are recorded as impairments in that fiscal period.



Statement of Cash Flows


For purposes of the statement of cash flows, we consider all highly liquid investments (i.e., investments which, when purchased, have original maturities of three months or less) to be cash equivalents.

Fair Value of Financial Instruments




Our financial instruments consist of cash and cash equivalents. The fair value
of cash and cash equivalents approximates the recorded amounts because of the
liquidity and short-term nature of these items.

28




Recent Accounting Pronouncements

We have reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe that any future adoption of such pronouncements will have a material impact on our financial condition or the results of our operations.

© Edgar Online, source Glimpses

Source : http://www.4-traders.com/AMERICAN-CRYOSTEM-CORP-10323125/news/AMERICAN-CRYOSTEM-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-PLAN-OF-OPERATIO-24980276/

11072
Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Source:4-Traders

Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Source:Seeking Alpha

Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research

Source:Seeking Alpha

Anti Aging Market Is Estimated To Be Worth USD 191.7 Billion Globally By 2019: Transparency Market Research